IFOM Publications Claudio Vernieri
  1. Home
  2. Research
  3. Publications
  4. Publications Claudio Vernieri

Publications Claudio Vernieri

Selected publications

  1. Pusceddu S, Vernieri C, Di Maio M, Prinzi N, Torchio M, Corti F, Coppa J, Buzzoni R, Di Bartolomeo M, Milione M, Regnault B, Truong Thanh XM, Mazzaferro V, de Braud F.
    Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study.
    Cancers (Basel). 2021 Dec 23;14(1):69. doi: 10.3390/cancers14010069. PMID: 35008233 Free PMC article.

  2. Vernieri C, Fucà G, Ligorio F, Huber V, Vingiani A, Iannelli F, Raimondi A, Rinchai D, Frigè G, Belfiore A, Lalli L, Chiodoni C, Cancila V, Zanardi F, Ajazi A, Cortellino S, Vallacchi V, Squarcina P, Cova A, Pesce S, Frati P, Mall R, Corsetto PA, Rizzo AM, Ferraris C, Folli S, Garassino MC, Capri G, Bianchi G, Colombo MP, Minucci S, Foiani M, Longo VD, Apolone G, Torri V, Pruneri G, Bedognetti D, Rivoltini L, de Braud F.
    Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer.
    Cancer Discov. 2022 Jan;12(1):90-107. doi: 10.1158/2159-8290.CD-21-0030. Epub 2021 Nov 17. PMID: 34789537 Free article.

  3. Salvadori G, Zanardi F, Iannelli F, Lobefaro R, Vernieri C, Longo VD.
    Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape.
    Cell Metab. 2021 Nov 2;33(11):2247-2259.e6. doi: 10.1016/j.cmet.2021.10.008. PMID: 34731655 Free PMC article.

  4. Pupa SM, Ligorio F, Cancila V, Franceschini A, Tripodo C, Vernieri C, Castagnoli L.
    HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness.
    Cancers (Basel). 2021 Sep 24;13(19):4778. doi: 10.3390/cancers13194778. PMID: 34638263 Free PMC article. Review.

  5. Ajazi A, Bruhn C, Shubassi G, Lucca C, Ferrari E, Cattaneo A, Bachi A, Manfrini N, Biffo S, Martini E, Minucci S, Vernieri C, Foiani M.
    Endosomal trafficking and DNA damage checkpoint kinases dictate survival to replication stress by regulating amino acid uptake and protein synthesis.
    Dev Cell. 2021 Sep 27;56(18):2607-2622.e6. doi: 10.1016/j.devcel.2021.08.019. Epub 2021 Sep 16. PMID: 34534458

  6. Valdemarin F, Caffa I, Persia A, Cremonini AL, Ferrando L, Tagliafico L, Tagliafico A, Guijarro A, Carbone F, Ministrini S, Bertolotto M, Becherini P, Bonfiglio T, Giannotti C, Khalifa A, Ghanem M, Cea M, Sucameli M, Murialdo R, Barbero V, Gradaschi R, Bruzzone F, Borgarelli C, Lambertini M, Vernieri C, Zoppoli G, Longo VD, Montecucco F, Sukkar SG, Nencioni A.
    Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment.
    Cancers (Basel). 2021 Aug 9;13(16):4013. doi: 10.3390/cancers13164013. PMID: 34439167 Free PMC article.

  7. Dameri M, Ferrando L, Cirmena G, Vernieri C, Pruneri G, Ballestrero A, Zoppoli G. Int J Mol Sci.
    Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer.
    2021 Jul 1;22(13):7154. doi: 10.3390/ijms22137154. PMID: 34281208 Free PMC article. Review.

  8. Ligorio F, Pellegrini I, Castagnoli L, Vingiani A, Lobefaro R, Zattarin E, Santamaria M, Pupa SM, Pruneri G, de Braud F, Vernieri C.
    Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer.
    Cancer Lett. 2021 Jul 28;511:77-87. doi: 10.1016/j.canlet.2021.04.023. Epub 2021 May 5. PMID: 33961924

  9. Ligorio F, Zambelli L, Bottiglieri A, Castagnoli L, Zattarin E, Lobefaro R, Ottini A, Vingiani A, Pupa SM, Bianchi GV, Capri G, Pruneri G, de Braud F,Vernieri C.
    Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients.
    Ther Adv Med Oncol. 2021 Apr 16;13:17588359211006960. doi: 10.1177/17588359211006960. eCollection 2021. PMID: 33948122 Free PMC article.

  10. Ligorio F, Fucà G, Zattarin E, Lobefaro R, Zambelli L, Leporati R, Rea C, Mariani G, Bianchi GV, Capri G, de Braud F,Vernieri C.
    The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab.
    Cancers (Basel). 2021 Apr 19;13(8):1964. doi: 10.3390/cancers13081964. PMID: 33921727 Free PMC article.

  11. Vernieri C, Nichetti F, Lalli L, Moscetti L, Giorgi CA, Griguolo G, Marra A, Randon G, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruneri G, Mariani L, de Braud F.
    Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET).
    Clin Cancer Res. 2021 Jun 15;27(12):3443-3455. doi: 10.1158/1078-0432.CCR-20-4928. Epub 2021 Mar 30. PMID: 33785482 Free article.

  12. Riccardo Lobefaro, Emma Zattarin, Federico Nichetti, Michele Prisciandaro, Francesca Ligorio, Marta Brambilla, Pierangela Sepe, Francesca Corti, Giorgia Peverelli, Arianna Ottini, Teresa Beninato, Laura Mazzeo, Carmen G Rea, Gabriella Mariani, Filippo de Braud, Giulia V Bianch, Claudio Vernieri, Giuseppe Capri
    Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis
    Ther Adv Med Oncol. 2020 Dec 7;12:1758835920970081. doi: 10.1177/1758835920970081. eCollection 2020.

  13. Emma Zattarin, Rita Leporati, Francesca Ligorio, Riccardo Lobefaro, Andrea Vingiani, Giancarlo Pruneri, Claudio Vernieri
    Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications
    Cells. 2020 Dec 9;9(12):2644. doi: 10.3390/cells9122644.

  14. Cristina Borzi, Giulia Galli, Monica Ganzinelli, Diego Signorelli, Claudio Vernieri, Marina Chiara Garassino, Gabriella Sozzi, Massimo Moro
    Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment
    Pharmaceuticals (Basel). 2020 Nov 13;13(11):385. doi: 10.3390/ph13110385.

  15. Marianna Sirico, Ottavia Bernocchi, Navid Sobhani, Fabiola Giudici, Silvia P Corona, Claudio Vernieri, Federico Nichetti, Maria Rosa Cappelletti, Manuela Milani, Carla Strina, Valeria Cervoni, Giuseppina Barbieri, Nicoletta Ziglioli, Martina Dester, Giulia Valeria Bianchi, Filippo De Braud, Daniele Generali
    Early Changes of the Standardized Uptake Values (SUV max) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
    Cancers (Basel). 2020 Nov 10;12(11):3314. doi: 10.3390/cancers12113314.

  16. Claudia Borreani, Sara Alfieri, Gabriele Infante, Rosalba Miceli, Paola Mariani, Marco Bosisio, Claudio Vernieri, Giulia V Bianchi, Giuseppe Capri
    Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters
    Oncology. 2020 Sep 29;1-12. doi: 10.1159/000509651. Online ahead of print.

  17. Vernieri C, Ligorio F, Zattarin E, Rivoltini L, de Braud F.
    Fasting-mimicking diet plus chemotherapy in breast cancer treatment.
    Nat Commun. 2020 Aug 26;11(1):4274. doi: 10.1038/s41467-020-18194-1. PMID: 32848145 Free PMC article.

  18. Pusceddu S, Vernieri C, Prinzi N, Torchio M, Coppa J, Antista M, Niger M, Milione M, Giacomelli L, Corti F, Prisciandaro M, Monteleone M, Colombo E, Di Bartolomeo M, de Braud F.
    The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence.
    Therap Adv Gastroenterol. 2020 Jul 31;13:1756284820927271. doi: 10.1177/1756284820927271. eCollection 2020. PMID: 32821286 Free PMC article. Review.

  19. Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, De Petris L, Yachnin J, Massard C, Opdam FL, Schlenk R, Vernieri C, Garralda E, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium, Calvo F, Fröhling S, Eggermont A, Apolone G, Voest EE, Caldas C, Tabernero J, Ernberg I, Rodon J, Lehtiö J.
    Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal.
    Nat Med. 2020 Jul;26(7):992-994. doi: 10.1038/s41591-020-0969-2. PMID: 32632195 No abstract available.

  20. Caffa I, Spagnolo V, Vernieri C, Valdemarin F, Becherini P, Wei M, Brandhorst S, Zucal C, Driehuis E, Ferrando L, Piacente F, Tagliafico A, Cilli M, Mastracci L, Vellone VG, Piazza S, Cremonini AL, Gradaschi R, Mantero C, Passalacqua M, Ballestrero A, Zoppoli G, Cea M, Arrighi A, Odetti P, Monacelli F, Salvadori G, Cortellino S, Clevers H, De Braud F, Sukkar SG, Provenzani A, Longo VD, Nencioni A.
    Fasting-mimicking diet and hormone therapy induce breast cancer regression.
    Nature. 2020 Jul;583(7817):620-624. doi: 10.1038/s41586-020-2502-7. Epub 2020 Jul 15. PMID: 32669709

  21. Zattarin E, Vernieri C.
    Sarcopenia and monocyte-to-lymphocyte ratio as prognostic factors in early-stage breast cancer.
    Ann Transl Med. 2020 Jun;8(12):737. doi: 10.21037/atm.2020.03.171. PMID: 32647662 Free PMC article. No abstract available.

  22. Vernieri C, Ganzinelli M, Rulli E, Farina G, Bettini AC, Bareggi C, Rosso L, Signorelli D, Galli G, Lo Russo G, Proto C, Moro M, Indraccolo S, Busico A, Sozzi G, Torri V, Marabese M, Massimo B, Garassino MC; TAILOR trialists.
    LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial.
    ESMO Open. 2020 May;5(3):e000748. doi: 10.1136/esmoopen-2020-000748. PMID: 32467099 - Free article.

  23. D'Amico S, Krasnowska EK, Manni I, Toietta G, Baldari S, Piaggio G, Ranalli M, Gambacurta A, Vernieri C, Di Giacinto F, Bernassola F, de Braud F, Lucibello M.
    DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines.
    Cells. 2020 May 19;9(5):E1260. doi: 10.3390/cells9051260. PMID: 32438775 - Free article.

  24. Di Tano M, Raucci F, Vernieri C, Caffa I, Buono R, Fanti M, Brandhorst S, Curigliano G, Nencioni A, de Braud F, Longo VD.
    Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers.
    Nat Commun. 2020 May 11;11(1):2332. doi: 10.1038/s41467-020-16243-3. PMID: 32393788 Free PMC article.

  25. Mirabile A, Rivoltini L, Daveri E, Vernieri C, Mele R, Porcu L, Lazzari C, Bulotta A, Viganò MG, Cascinu S, Gregorc V.
    Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence.
    Cancers (Basel). 2020 May 4;12(5):E1153. doi: 10.3390/cancers12051153. PMID: 32375310 Free article. Review.

  26. Vernieri C, Corti F, Nichetti F, Ligorio F, Manglaviti S, Zattarin E, Rea CG, Capri G, Bianchi GV, de Braud F.
    Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
    Breast Cancer Res. 2020 Apr 6;22(1):33. doi: 10.1186/s13058-020-01271-0. Review. PMID: 32252811

  27. Vernieri C, Prisciandaro M, Nichetti F, Lobefaro R, Peverelli G, Ligorio F, Zattarin E, Cona MS, Sepe P, Corti F, Manglaviti S, Brambilla M, Re B, Belfiore A, Pruneri G, Celio L, Mariani G, Bianchi GV, Rivoltini L, Capri G, de Braud F.
    Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer.
    Cancers (Basel). 2020 Mar 6;12(3). pii: E617. doi: 10.3390/cancers12030617. PMID: 32155941

  28. Castagnoli L, De Santis F, Volpari T, Vernieri C, Tagliabue E, Di Nicola M, Pupa SM.
    Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure.
    Cells. 2020 Feb 27;9(3). pii: E555. doi: 10.3390/cells9030555. Review. PMID: 32120774

  29. Kong WJ, Vernieri C, Foiani M, Jiang JD.
    Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders.
    Pharmacol Ther. 2020 Jan 27:107496. doi: 10.1016/j.pharmthera.2020.107496. [Epub ahead of print] Review. PMID: 32001311

  30. Vernieri C, Pusceddu S, de Braud F.
    Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors.
    Front Oncol 2019;9:902

  31. Fucà G, Mariani L, Lo Vullo S, Galli G, Berardi R, Di Nicola M, Vernieri C et al.
    Weighing the prognostic role of hyponatriemia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study.
    Sci Rep 2019;9(1):12993. PMID: 31506579

  32. Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R, Colombo MP, Lamolinara A, Iezzi M, Ladomery M, Vernieri C, et al.
    Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.
    Cell Oncol (Dordr) 2019. PMID: 31376137

  33. Rivoltini L, Vernieri C, Huber V.
    The AURORA of a New Way to Value Myeloid Immunosuppression in Cancer.
    Cancer Res. 2019;79(13):3169-3171. PMID: 31262832

  34. Vernieri C, Milano M, Brambilla M, et al.
    Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives.
    Critical Reviews in Oncology/Hematology 2019;139:53-66. PMID: 31112882.

  35. Corno A, Chiroli E, Gross F, Vernieri C, et al.
    Cellular response upon proliferation in the presence of an active mitotic checkpoint.
    Life Science Alliance 2019;2(3). PMID: 31068378

  36. Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, et al.
    Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
    ESMO Open 2019;4(1). PMID: 30964126

  37. Cona MS, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A, Poggi MM, Raggi D, Randon G, Ratta R, Signorelli D, Vernieri C, et al.
    Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies.
    Cancers (Basel) 2019 Feb 14;1(2). PMID: 30769874

  38. Vernieri C, Prisciandaro M, Milano M, et al.
    Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles.
    Clin Breast Cancer 2019;19(2):e306-e318. PMID: 30635175

  39. Vernieri C, Signorelli D, Galli G, et al.
    Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.
    Clin Lung Cancer 2019;20(3)e413-e417. PMID 30617039

  40. Vernieri C, Galli F, Ferrari L, et al.
    Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.
    Oncologist 2019;24(3):385-393. PMID: 30606884

  41. Vernieri C, Pusceddu S, Fucà G, et al.
    Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).
    Int J Cancer 2019;144(7):1704-1712. PMID: 30520016

  42. Moro M, Caiola E, Ganzinelli M, Zulato E, Rulli E, Marabese M, Centonze G, Busico A, Pastorino U, de Braud FG, Vernieri C, et al.
    Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
    J Thorac Oncol 2018;13(11):1692-1704. PMID: 30149143

  43. Castagnoli L, Iorio E, Dugo M, Koschorke A, Faraci S, Canese R, Casalini P, Nanni P, Vernieri C, et al.
    Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.
    J Cell Physiol 2019; 234(2):1768-1779. PMID: 30132876

  44. Brighi N, La Rosa S, Rossi G, Grillo F, Pusceddu S, Rinzivillo M, Spada F, Tafuto S, Massironi S, Faggiano A, Antonuzzo L, Santini D, Sessa F, Maragliano R, Gelsomino F, Albertelli M, Vernieri C, Panzuto F, Fazio N, De Divitiis C, Lamberti G, Colao A, Fave GD, Campana D.
    Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study.
    Ann Surg. 2018 Jul 10. PMID: 29995678

  45. Vernieri C, Mennitto A, Prisciandaro M., et al.
    The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
    Sci Rep. 2018 Jun 7;8(1):8703. PMID: 29880896

  46. Pusceddu S, Vernieri C et al.
    Metformin Use Associates With Longer Progression-free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
    Gastroenterology 2018;155(2):479-489. PMID: 29655834

  47. Pusceddu S, Barretta F, Trama A, Botta L, Milione M et al.
    A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors
    Endocr Relat Cancer. 2018 Jun;25(6):607-618. PMID: 29559553

  48. Vernieri C, Nichetti F et al.
    Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives
    Crit Rev Oncol Hematol. 2018 Mar;123:57-73. PMID: 29482780

  49. Bonaiuti P, Chiroli E, Gross F, Corno A, Vernieri C et al.
    Cells Escape an Operational Mitotic Checkpoint through a Stochastic Process.
    Curr Biol. 2018 Jan 8;28(1):28-37.e7. PMID: 29249657

  50. Oddo D, Siravegna G, Gloghini A, Vernieri C et al.
    Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.
    Br J Cancer. 2017 Jul 25;117(3):347-352. PMID: 28654634

  51. Vernieri C, Milano M, Mennitto A et al.
    Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, moncentric, retrospective study.
    Breast Cancer Res Treat. 2017 Sep;165(2):365-373. PMID: 28616768

  52. Pusceddu S, Prinzi N, Lo Russo G, Femia D, Milione M, Perrone F, Tamborini E, Concas L, Pulice I, Vernieri C, Corti F, Buzzoni R, de Braud F.
    Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors.
    Future Oncol. 2017 Aug;13(19):1677-1683. PMID: 28580793

  53. Pusceddu S, Verzoni E, Prinzi N, Mennitto A, Femia D, Grassi P, Concas L, Vernieri C, Lo Russo G, Procopio G.
    Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.
    Ther Adv Med Oncol. 2017 Mar;9(3):183-188. PMID: 28344663

  54. Vernieri C, Casola S, Foiani M, et al:
    Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.
    Cancer Discovery 2016;6(12):1315-1333. PMID: 27872127

  55. Pietrantonio F, Vernieri C, Siravegna G, et al
    Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer.
    Clin Cancer Res 2017;23(10:2414-2422. PMID: 27780856

  56. Pusceddu, S., Buzzoni, R., Vernieri, C. et al.
    Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
    Future Oncol 2016;12(10):1251-60. PMID: 26890290.

  57. Crespo, C. L., Vernieri, C. et al.
    The PAR complex controls the spatiotemporal dynamics of F-actin and the MTOC in directionally migrating leukocytes.
    J Cell Sci 2014;127:4381-4395. PMID: 25179599.

  58. Vernieri, C., Chiroli, E., Francia, V., Gross, F. & Ciliberto, A
    Adaptation to the spindle checkpoint is regulated by the interplay between Cdc28/Clbs and PP2ACdc55.
    J Cell Biol 2013;202, 765-778. PMID: 23999167

  59. Santaguida S, Vernieri C, Villa F, Ciliberto A, Musacchio A.
    Evidence that Aurora B is implicated in spindle checkpoint signaling independently or error correction.
    EMBO J. 2011 Apr 20;30(8):1508-19. PMID: 21407176

Uptade: Jan 2021

vernieri Lab Vernieri Lab Researcher Research program Contact the researcher